PAVmed Reports Q1 2026 Net Loss of $7.0M, Reinforcing Going Concern Warning
PAVM sits 17% above its 52-week low of $6.
Summary
PAVmed Inc. reported a significant net loss of $7.0 million for Q1 2026, with minimal revenue, underscoring its precarious financial position and the previously issued going concern warning.
Key Events · Earnings and Guidance · PAVM
-
Significant Net Loss Reported
PAVmed Inc. reported a GAAP net loss attributable to common stockholders of approximately $7.0 million, or $(4.42) per diluted common share, for the first quarter ended March 31, 2026. This follows a news report on May 14, 2026, which first disclosed these figures.
-
Minimal Revenue Generation
The company recognized only $22,000 in revenue for Q1 2026, indicating limited commercial traction for its products.
-
Low Cash Position
PAVmed had cash and cash equivalents of $6.5 million as of March 31, 2026, a modest increase from $1.5 million at December 31, 2025, but still low given its operating expenses.
-
Subsidiary Updates
Veris Health is progressing its implantable physiological monitor towards FDA submission and expanding commercial engagement. Lucid Diagnostics reported $1.3 million in EsoGuard revenue and strengthened its balance sheet with a $17 million public offering, extending its runway into 2027.
Analysis · PAVM · Industrial Applications And Services
PAVmed's Q1 2026 financial results reveal a substantial net loss of $7.0 million, which is significant relative to its market capitalization. This reinforces the 'going concern' warning previously disclosed in the company's 10-K filing on March 27, 2026, highlighting ongoing financial challenges despite some progress in its subsidiaries. The low cash balance for PAVmed itself indicates continued reliance on external financing.
At the time of this filing, PAVM was trading at $7.04 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $41.2M. The 52-week trading range was $6.00 to $28.44. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.